Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma

Table 1 Clinical characteristics of patients n (%)

Variables	BCLC stage 0 (n = 40)	BCLC stage A (n = 89)	P value
Age (yr)	59.5 ± 10.0	61.7 ± 11.0	0.208
Male	28 (73)	64 (67)	0.836
Etiology
HBV	18 (45)	40 (45)	0.822
HCV	5 (13)	9 (10)
Alcohol	10 (25)	21 (24)
Others	7 (17)	19 (21)
Child-Pugh score	5.4 ± 1.0	5.9 ± 0.9	0.976
Cirrhosis	38 (95)	73 (85)	0.146
Albumin (g/dL)	3.9 ± 0.7	3.9 ± 2.2	0.904
AST (IU/L)	67.7 ± 68.3	91.4 ± 217.2	0.503
ALT (IU/L)	43.2 ± 40.1	62.2 ± 133.1	0.378
TB (mg/dL)	1.2 ± 1.3	1.2 ± 0.9	0.971
GGT (IU/L)	98.9 ± 98.9	136.3 ± 244.9	0.398
N of TACE treatment	2.1 ± 1.5	2.7 ± 2.5	0.066
AFP (ng/mL)	75.6 ± 159.6	490.7 ± 1582.4	0.018
Greatest diameter of mass (cm)	1.4 ± 0.3	2.8 ± 1.0	< 0.001

BCLC: Barcelona Clinic Liver Cancer; HBV: Hepatitis B virus; HCV: Hepatitis C virus; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; TB: Total bilirubin; GGT: Gamma glutamyl transferase; AFP: α-fetoprotein.